| First author | Published year | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|---|
| Research question or objective clearly stated? | Study population clearly specified and defined? | Participation rate of eligible persons ≥ 50%? | Subjects selected or recruited from the same or similar population? | Sample size justification, power description or variance and effect estimates provided? | Exposure(s) of interest measured prior to outcome(s)? | Time frame sufficient for outcome to be shown if present? | ||
| Atrsaei | 2021 | Yes | Yes | Yes | Yes | NR | Yes | Yes |
| Bento | 2010 | Yes | Yes | NR | Yes | No | No | No |
| Chan | 2007 | Yes | Yes | Yes | Yes | NR | Yes | Yes |
| Cheng | 2014 | Yes | No | NR | Yes | No | No | No |
| Crozara | 2013 | Yes | Yes | NR | Yes | No | No | No |
| Crozara | 2016 | Yes | Yes | NR | Yes | Yes | No | No |
| Dietzel | 2015 | Yes | Yes | NR | Yes | No | No | No |
| Ejupi | 2017 | Yes | Yes | NR | Yes | No | No | No |
| Hsieh | 2023 | Yes | Yes | NR | Yes | NR | Yes | Yes |
| Kamo | 2019 | Yes | Yes | Yes | Yes | NR | No | No |
| Kemoun | 2002 | Yes | Yes | NR | Yes | No | Yes | Yes |
| Kera | 2020 | Yes | Yes | No | Yes | No | Yes | Yes |
| LaRoche | 2010 | Yes | No | NR | No | No | No | No |
| Palmer | 2015 | Yes | Yes | NR | Yes | Yes | No | No |
| Parsons | 2020 | Yes | Yes | Yes | Yes | No | Yes | Yes |
| Perry | 2007 | Yes | Yes | NR | No | No | No | No |
| Porto | 2022 | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Ribeiro | 2012 | Yes | Yes | NR | Yes | No | No | No |
| Skelton | 2002 | Yes | Yes | NR | No | No | No | No |
| Winger | 2023 | Yes | Yes | Yes | Yes | NR | Yes | Yes |
| First author | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
|---|---|---|---|---|---|---|---|---|
| Different levels of exposure examined in relation to outcome? | Exposure measures clearly defined, valid, reliable and implemented consistently? | Exposure(s) measured more than once over time? | Outcome measures clearly defined, valid, reliable and implemented consistently? | Outcome assessors blinded to exposure status of participants? | Loss of follow up after baseline ≤ 20%? | Key potential confounding variable measured and adjusted for? | Overall score | |
| Atrsaei | Yes | Yes | No | Yes | NR | NR | Yes | 10 |
| Bento | Yes | Yes | NA | Yes | NR | NA | Yes | 7 |
| Chan | Yes | Yes | No | Yes | NR | Yes | Yes | 11 |
| Cheng | Yes | Yes | NA | Yes | NR | NA | Yes | 6 |
| Crozara | No | Yes | NA | Yes | NR | NA | Yes | 6 |
| Crozara | Yes | Yes | NA | Yes | NR | NA | No | 7 |
| Dietzel | Yes | Yes | NA | Yes | NR | NA | Yes | 7 |
| Ejupi | No | Yes | NA | Yes | NR | NA | NA | 5 |
| Hsieh | Yes | Yes | No | Yes | NR | Yes | Yes | 10 |
| Kamo | Yes | Yes | NA | Yes | NR | NA | Yes | 8 |
| Kemoun | No | Yes | No | Yes | Yes | Yes | No | 9 |
| Kera | Yes | Yes | No | Yes | NR | NR | Yes | 9 |
| LaRoche | No | Yes | NA | Yes | NR | NA | NA | 3 |
| Palmer | No | Yes | NA | Yes | NR | NA | NA | 6 |
| Parsons | Yes | Yes | No | Yes | NR | No | Yes | 10 |
| Perry | No | Yes | NA | Yes | NR | NA | No | 4 |
| Porto | Yes | Yes | No | Yes | NR | Yes | Yes | 12 |
| Ribeiro | Yes | Yes | NA | Yes | NR | NA | NA | 6 |
| Skelton | No | Yes | NA | Yes | NR | NA | No | 4 |
| Winger | Yes | Yes | No | Yes | NR | Yes | Yes | 11 |
NR Not reported NA Not applicable